Vir Biotechnology Inc. (NASDAQ: VIR) reported Q2 EPS of ($0.80), $0.10 worse than the analyst estimate of ($0.70). Revenue for the quarter came in at $1.21 million versus the consensus estimate of $2.66 million.

2025 Financial Guidance

Based on current operating plans, the Company expects its cash, cash equivalents and investments to fund operations into mid-2027.

For earnings history and earnings-related data on Vir Biotechnology Inc. (VIR) click here.